# US 6,730,791 B2 · Antihistaminic piperidine derivatives and intermediates for the preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,791 B2
- Document ID: US6730791B2
- Status: Granted
- Kind: B2
- Application number: 10/104,149
- Filed: 2002-03-22
- Published: 2002-07-25
- Granted: 2004-05-04
- Earliest claimed: 1998-07-02
- Assignees: Aventis Pharmaceuticals Inc.
- Inventors: Timothy A. Ayers
- Web page: https://patentgrep.com/patent/US6730791B2

## CPC

- C07D 211/22: by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention relates to novel compounds of the following formula and a process for the preparation thereof. wherein X is Cl, Br or I.

## Claims

### Claim 1

A process for preparing a compound of the formula
wherein X is Cl, Br, or I;
comprising the steps of:
(a) reacting a compound of the formula
with a 4-halo-substituted butyrylhalide under Friedel-Crafts conditions to provide a mixture of para- and meta-substituted (4-halo-1-oxobutyl)-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I;
(b) selectively crystallizing and isolating substantially pure [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I;
(c) hydrolyzing the substantially pure [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide to provide a (cyclopropylcarbonyl)benzeneacetic acid of the formula
(d) esterifying the (cyclopropylcarbonyl)benzeneacetic acid to provide a (cyclopropylcarbonyl)benzeneacetic acid ester of the formula
wherein
R1 is C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
(e) acylating the (cyclopropylcarbonyl)benzeneacetic acid ester to provide a [4-(cyclopropylcarbonyl)phenyl]propanedioic acid diester of the formula
wherein
R1 is H;
R2 and R3 are each independently C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
(f) optionally alkylating the [4-(cyclopropylcarbonyl)phenyl]propanedioic acid diester to provide a [4-(cyclopropylcarbonyl)phenyl]propanedioic acid diester of the formula
wherein
R1 is C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched and R2 and R3 each independently C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
(g) reacting the [4-(cyclopropylcarbonyl)phenyl]propanedioic acid diester of the formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched
R2 and R3 are each independently C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched,
with a suitable hydrogen halide to produce a [4-(4-halo-1-oxo-butyl)phenyl]propanedioic acid diester of formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
R2 and R3 are each independently C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
X is Cl, Br or I;
(h) reacting the [4-(4-halo-1-oxo-butyl)phenyl]propanedioic acid diester with a compound of formula
to produce a [4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]phenyl]propanedioic acid diester compound of formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
R2 and R3 are each independently C1-C6alkyl wherein the C1-C8alkyl moiety is straight or branched; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof;
(i) reacting the [4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]phenyl]propanedioic acid diester compound with a suitable selective reducing agent to give a 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α-(hydroxymethyl)-benzeneacetic acid ester compound of formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
R2 is —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof; and
(j) optionally hydrolyzing the 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α-(hydroxymethyl)-benzeneacetic acid ester compound to produce a compound of formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched
R2 is —COOH; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof;
with the proviso that each of the keto groups present in the compounds described in steps c-h are optionally protected or unprotected.

### Claim 2 (depends on 1)

A process according to claim 1 wherein the [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide of step c) is [4-(4-chloro-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide,

### Claim 3 (depends on 1)

A process according to claim 1 wherein R1 of the compound produced in step j) is methyl.

### Claim 4

A process for preparing a compound of the formula
wherein X is Cl, Br, or I;
comprising the steps of:
(b) reacting a compound of the formula
with a 4-halo-substituted butyrylhalide under Friedel-Crafts conditions to provide a mixture of para- and meta-substituted (4-halo-1-oxobutyl)-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I;
(b) selectively crystallizing and isolating substantially pure [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I
(c) hydrolyzing the substantially pure [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide to provide a (cyclopropylcarbonyl)benzeneacetic acid of the formula
(d) esterifying the 4-(cyclopropylcarbonyl)benzene acetic acid to provide a corresponding 4-(cyclopropylcarbonyl)benzeneacetic acid ester of the formula
wherein
R1 is C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
(e) alkylating the 4-(cyclopropylcarbonyl)benzeneacetic acid ester with a suitable alkylating agent to provide a corresponding alkylated [4-(cyclopropylcarbonyl)phenyl]benzeneacetic acid ester
wherein
R1 is as previously defined herein and R2 and R3 are each independently C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
(f) ring-opening the alkylated [4-(cyclopropylcarbonyl)phenyl]benzene acetic acid ester to provide a corresponding [4-(4-halo-1-oxo-butyl)phenyl]benzene acetic acid ester of the formula
wherein
R1, R2 and R3 are as previously defined herein and X is Cl, Br or I;
(g) reacting the alkylated [4-(4-halo-1-oxo-butyl)phenyl]benzeneacetic acid ester with a compound of the formula
to produce a [4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]phenyl]benzeneacetic acid ester of the formula
wherein
R1, R2 and R3 are as previously defined herein; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof;
h) reacting the [4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl]phenyl]benzeneacetic acid ester with a suitable reducing agent to produce a 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]benzeneacetic acid ester of the formula
wherein
R1, R2 and R3 are as previously defined herein; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof;
i) optionally hydrolyzing the 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]benzeneacetic acid ester to produce a compound of the formula
wherein
R2 and R3 are as previously defined herein; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof;
with the proviso that each of the keto groups present in the compounds described in steps c-g are optionally protected or unprotected.

### Claim 5 (depends on 4)

A process according to claim 4 wherein the [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide of step c) is [4-(4-chloro-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide.

### Claim 6

In a process for the synthesis of a compound of the formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched;
R2 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof, using as an intermediate a compound of the formula
wherein
X is Cl, Br, or I;
the improvement wherein said intermediate compound was prepared according to the process comprising
(a) reacting a compound of the formula
with 4-halo-substituted butyrylhalide under Friedel-Crafts conditions to provide a mixture of para- and meta-substituted (4-halo-1-oxobutyl)-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I and
(b) selectively crystallizing and isolating substantially pure [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I.

### Claim 7 (depends on 6)

A process according to claim 6 wherein the 4-halo-substituted butyrylhalide is 4-chlorobutyrylchloride.

### Claim 8 (depends on 6)

A process according to claim 6 wherein the [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide provided in step b) is [4-(4-chloro-1-oxobutyl]N-methoxy-N-methyl-benzeneacetamide.

### Claim 9

In a process for the synthesis of a compound of the formula
wherein
R1 is H or C1-C6alkyl wherein the C1-C6alkyl moiety is straight or branched, and R2 and R3 are each independently C3-C6alkyl wherein the C3-C6alkyl moiety is straight or branched; or
stereoisomers or pharmaceutically acceptable acid addition salt thereof; using as an intermediate a compound of the formula
wherein
X is Cl, Br, or I;
the improvement wherein said intermediate compound was prepared according to the process comprising
(a) reacting a compound of the formula
with 4-halo-substituted butyrylhalide under Friedel-Crafts conditions to provide a mixture of para- and meta-substituted (4-halo-1-oxobutyl)-N-methoxy-N-methyl-benzeneacetamide of the formula
wherein
X is Cl, Br, or I; and
(b) selectively crystallizing and isolating substantially pure [4-(4-halo-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide of the formula

### Claim 10 (depends on 9)

A process according to claim 9 wherein the 4-halo-substituted butyrylhalide is 4-chlorobutyrylchloride.

### Claim 11 (depends on 9)

A process according to claim 9 wherein [4-(4-halo-1-oxobutyl]-N-methoxy-N-methyl-benzeneacetamide is [4-(4-chloro-1-oxobutyl)]-N-methoxy-N-methyl-benzeneacetamide.

### Claim 12 (depends on 9)

A process according to claim 9 wherein R2 and R3 are methyl and R1 is hydrogen.
